BOXBOROUGH, MASSACHUSETTS, UNITED STATES, June 4, 2021 Vibalogics, a global virotherapy contract development and manufacturing organization (CDMO), Arranta Bio (“Arranta”), the leading microbiome CDMO, along with Lincoln Property Company (LPC) today made a significant donation to the Boxborough Conservation Trust (BCT) a private, nonprofit 501(c)(3) organization founded in 1997 to preserve and protect Boxborough Massachusetts’s rural character and natural…
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of a 130,000-square-feet facility in Boxborough, Massachusetts, to complement its existing facilities in Watertown, Massachusetts and Gainesville, Florida, bringing the total manufacturing capacity at Arranta to over 230,000 square feet. Arranta closed an oversubscribed Series B equity financing from…
Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the promotion of David Stevens to President and Chief Operating Officer (COO) and the appointment of Iain Baird to Arranta Bio’s Board of Directors. “I am delighted to announce the promotion of David Stevens and to share that Iain Baird is joining Arranta…
Arranta Bio recently announced the launch of a corporate social responsibility (CSR) program, Arranta Bio Cares, and appointed Susan Surabian as the initiative’s leader. As a champion of diversity and inclusion from its inception, the company’s CSR program will continue to prioritize efforts promoting Arranta Bio Cares’ core pillars. Firstly, the company is striving for a welcoming, diverse culture that fosters racial, social and gender equality. Next, we are strengthening local communities in MA…
Concluding a year of growth, challenge and agility, we’re proud to announce that Arranta Bio has been a named Life Science Company of the Year finalist in the Gainesville Chamber of Commerce 2020 Business Awards. This honor marks the second year Arranta, which acquired Gainesville-based biotechnology CDMO Captozyme in November 2019, has been chosen for…
Watertown, MA (USA) – September 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to establish a state of the art, multi-product, commercial-ready manufacturing facility that will supply…
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the addition of Shailesh Maingi to Arranta’s board as an Independent Director. Shailesh Maingi is the founder and CEO of Kineticos Life Sciences, a boutique advisory focused on strategy, licensing and commercial product launch that he established in 2007. In 2019 he founded the…
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), today announced the completion of its microbiome process development lab expansion project and a commitment to add additional early- clinical GMP capacity at its Center of Excellence for Microbiome Process Development and Early Clinical Supply. Arranta has completed the expansion of purpose-built microbiome…
Watertown, MA – January 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity…
Watertown, MA – November [13], 2019: Arranta Bio (“Arranta”) announced today the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta. Formed in 2009, Captozyme has…
